A personal curriculum is a self-directed learning plan focused on interests and growth, not grades, explains columnist Candace Semien.

Biogen reports strong enrollment progress in the AMETHYST clinical trial testing litifilimab in cutaneous lupus erythematosus ...

Unprepared for a recent hospitalization, columnist Candace Semien is now pre-packing essential items into a go bag.

If you're living with a chronic illness like lupus, workplace accommodations are your legal right, explains columnist.

Scientist Akiko Iwasaki will receive the Dr. William E. Paul Distinguished Innovator Award (DIA) to investigate whether ancient viral DNA in our cells is a potential trigger for lupus. The $1 million ...

Telitacicept, a B-cell-targeting therapy developed by RemeGen, outperformed a placebo at reducing the severity of systemic lupus erythematosus (SLE) in a Phase 3 clinical trial in China, the company ...

Lupuzor (rigerimod, or IPP-201101) combined with standard therapy did not demonstrate a statistically significant response rate in systemic lupus erythematosus (SLE) patients over standard care alone, ...

Lupus Therapeutics is partnering with AbbVie for the Phase 3 clinical program of upadacitinib for people with systemic lupus erythematosus (SLE). “The partnership with AbbVie will support the ...

Let’s start with a little story, shall we? It’s currently 142 F outside. OK, that might be a slight exaggeration, but not by much. I’m living through one of the most brutal heat waves my area has seen ...

Lupus News Today is a digital platform intended to provide the lupus community with the most recent news and information, as well as first-hand community perspectives from our patient and caregiver ...

Lupkynis (voclosporin) is now approved in Japan to treat lupus nephritis, a complication of lupus marked by kidney damage and inflammation. The Japanese Ministry of Health, Labour, and Welfare ...

A Phase 2 clinical trial testing Galápagos‘ experimental oral therapy GLPG3667 in people with systemic lupus erythematosus (SLE) has failed to meet its main goal, although some promising trends were ...